Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Indacaterol + mometasonefluroate | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Indacaterol and Mometasonefluroate (low dose) | Drug | Participants are administered 125 µg indacaterol + mometasonefluroate |
|
| Measure | Description | Time Frame |
|---|---|---|
| Power output during sprint testing | Power output measured in Watts during a sprint on a bike ergometer | Through study completion, an average of 3 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Power output during time trial | Mean power output measured in Watts during a time trial on a bike ergometer | Through study completion, an average of 3 weeks |
| Forced Expiratory Volume in 1 second (FEV1) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Morten Hostrup, PhD | Contact | +4535321595 | mhostrup@nexs.ku.dk |
| Name | Affiliation | Role |
|---|---|---|
| Morten Hostrup, PhD | University of Copenhagen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| August Krogh Building | Recruiting | Copenhagen | 2100 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C510790 | indacaterol |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Participants are administered placebo |
|
| Indacaterol and Mometasonefluroate (high dose) | Drug | Participants are administered 500 µg indacaterol + mometasonefluroate |
|
FEV1 measured by spirometry
| Through study completion, an average of 3 weeks |
| Quadriceps strength | Maximal torque (Nm) achieved during isometric contraction | Through study completion, an average of 3 weeks |
| Respiratory muscle function | Mouth inspiratory and expiratory pressures (MD Diagnostics, RP-check, handheld respiratory pressure meter) | Through study completion, an average of 3 weeks |